Itraconazole
- Generic Name
- Itraconazole
- Brand Names
- Sporanox, Tolsura
- Drug Type
- Small Molecule
- Chemical Formula
- C35H38Cl2N8O4
- CAS Number
- 84625-61-6
- Unique Ingredient Identifier
- 304NUG5GF4
- Background
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
- Indication
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
- Associated Conditions
- Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study
- Conditions
- Relapsed or Refractory Lymphoma
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 28
- Registration Number
- NCT05720767
- Locations
- đēđ¸
PPD Austin, Austin, Texas, United States
A Study of IBI351 in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05699993
- Locations
- đ¨đŗ
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 104
- Registration Number
- NCT05691699
- Locations
- đēđ¸
Acpru /Id# 251279, Grayslake, Illinois, United States
A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558
- Conditions
- COVID-19 Pneumonia
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT05685719
- Locations
- đ¨đŗ
Zhejiang Xiaoshan Hospital, Hangzhou, Zhejiang, China
To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100
- Conditions
- Bacterial Infections
- Interventions
- Drug: BV100 (300 mg)
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- BioVersys AG
- Target Recruit Count
- 16
- Registration Number
- NCT05684718
- Locations
- đđē
CRU Hungary Kft., Early Phase Unit, Kistarcsa, Hungary
A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
- Conditions
- Prostate AdenocarcinomaProstate CancerProstate Cancer Metastatic
- Interventions
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 100
- Registration Number
- NCT05679388
- Locations
- đēđ¸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05667662
- Locations
- đēđ¸
Southern Illinois University Center for Clinical Research, Springfield, Illinois, United States
đēđ¸Bensch Clinical Research, Stockton, California, United States
đŦđ§University Hospitals Birmingham - Heartlands Hospital, Birmingham, West Midlands, United Kingdom
Itraconazole to Prevent Recurrent Barrett's Esophagus
- Conditions
- Barrett Oesophagitis With Dysplasia
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT05609253
- Locations
- đēđ¸
University of Kansas Medical Center, Kansas City, Kansas, United States
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
- Conditions
- Relapsed or Refractory Lymphoma
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 59
- Registration Number
- NCT05602597
- Locations
- đēđ¸
QPS- Miami, Miami, Florida, United States
Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 36
- Registration Number
- NCT05594602
- Locations
- đēđ¸
ICON, plc., Lenexa, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.